Biomarkers in medicine · 2026
The relationship between serum neopterin levels and disease activity in patients with spondyloarthropathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kılıç Ayza, Koçak Ulucaköy Rezan, Osmanov Zakir, Çobanoğlu İdil Melis, Aybay Cemalettin, Göğüş Feride Nur
Аннотация
OBJECTIVE: Biomarkers that accurately reflect disease activity and inflammatory burden are needed, particularly in the early stages of spondyloarthropathy (SpA). This study aimed to evaluate the association between serum neopterin levels and disease activity indices in patients with SpA.
METHODS: This cross-sectional study included 84 participants based on a priori sample size estimation: 21 patients with axial SpA (axSpA), 21 with peripheral SpA (pSpA), 21 with active rheumatoid arthritis (RA) and 21 healthy controls (HC). Disease activity in SpA was assessed using the Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). A disease activity was assessed using the Disease Activity Score in 28 Joints (DAS28). Serum neopterin levels were measured by Enzyme-Linked Immunosorbent Assay.
RESULTS: Serum neopterin levels differed significantly among the groups (post-hoc, p = 0.007), with higher levels observed in patients with active RA than in those with axSpA, and no significant associations were found between neopterin levels and disease activity indices in either axial or peripheral SpA.
CONCLUSION: In the present study cohort, no significant association was observed between serum neopterin levels and disease activity in patients with axial or peripheral SpA.
METHODS: This cross-sectional study included 84 participants based on a priori sample size estimation: 21 patients with axial SpA (axSpA), 21 with peripheral SpA (pSpA), 21 with active rheumatoid arthritis (RA) and 21 healthy controls (HC). Disease activity in SpA was assessed using the Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). A disease activity was assessed using the Disease Activity Score in 28 Joints (DAS28). Serum neopterin levels were measured by Enzyme-Linked Immunosorbent Assay.
RESULTS: Serum neopterin levels differed significantly among the groups (post-hoc, p = 0.007), with higher levels observed in patients with active RA than in those with axSpA, and no significant associations were found between neopterin levels and disease activity indices in either axial or peripheral SpA.
CONCLUSION: In the present study cohort, no significant association was observed between serum neopterin levels and disease activity in patients with axial or peripheral SpA.